Diagnosis and Management of JAK2 V617F‑Positive Myeloproliferative Neoplasms

1. Pathophysiology

• The JAK2 V617F mutation causes constitutive activation of the JAK‑STAT signaling pathway, leading to uncontrolled proliferation of bone‑marrow cells, especially megakaryocytes. 1

2. Differential Diagnosis in Patients with Persistent Thrombocytosis and JAK2 V617F

• In this setting three primary myeloproliferative neoplasms must be considered:
  
  • Polycythemia vera (PV) – JAK2 V617F is present in >95 % of cases. 1
  • Essential thrombocythemia (ET) – JAK2 V617F is detected in approximately 50‑60 % of patients. 1
  • Primary myelofibrosis (PMF) – JAK2 V617F is also found in roughly 50‑60 % of patients. 1

3. WHO Diagnostic Criteria for Essential Thrombocythemia (ET)

• Diagnosis requires all four of the following (WHO 2016) criteria:
  *These criteria are supported by the Blood, Annals of Oncology, and Journal of Clinical Oncology publications. 1, 2, 3

4. Excluding Polycythemia Vera

• Hemoglobin thresholds for PV diagnosis are > 18.5 g/dL in men and > 16.5 g/dL in women; values above these limits mandate PV work‑up. 1, 3, 4

5. Risk Stratification in ET (IPSET‑thrombosis)

• Scoring system (Leukemia 2018):

  • Age ≥ 60 years – 1 point.
  • Prior thrombosis – 2 points.
  • Presence of JAK2 V617F – 2 points.
  • Cardiovascular risk factors (smoking, diabetes, hypertension, hypercholesterolemia) – 1 point.
    *Reference: 4, 5

• Risk categories:

  • Low risk – 0‑1 point.
  • Intermediate risk – 2 points.
  • High risk – ≥ 3 points.
    *Reference: 4

6. Therapeutic Recommendations by Risk Level

6.1 High‑Risk ET (age ≥ 60 yr or prior thrombosis)

• First‑line cytoreductive therapy with hydroxyurea or interferon‑α; target platelet count within the normal range.
• Low‑dose aspirin 75‑100 mg daily for antiplatelet protection.
  *Reference: 4, 5

6.2 Low‑Risk ET (age < 60 yr and no prior thrombosis)

• Low‑dose aspirin 75‑100 mg daily.
• Observation without cytoreductive therapy.
  *Reference: 4, 5

6.3 Indications for Cytoreduction Even in Low‑Risk Patients

• Symptomatic splenomegaly, progressive leukocytosis or thrombocytosis, or intolerance/inadequate response to phlebotomy (in PV).
  *Reference: 6

7. Bone‑Marrow Evaluation Prior to Cytoreduction

• Mandatory pre‑treatment biopsy to grade reticulin fibrosis (scale 0‑3) and exclude PMF.
  Typical histology: ET – large, mature megakaryocytes; PMF – atypical megakaryocytes with abnormal nucleus‑to‑cytoplasm ratio.
  Reference: 2, 7

8. Follow‑Up and Monitoring

• Clinical review every 3–6 months with:
  
  • Complete blood count to assess treatment response and cytopenias.
  • Physical exam or ultrasound for spleen size.
  • Evaluation for thrombotic or bleeding complications.
    *Reference: 6, 8

9. Special Clinical Situations

9.1 Extreme Thrombocytosis (> 1500 × 10⁹/L)

• High risk of acquired von Willebrand disease and bleeding; consider temporary discontinuation of aspirin until platelet count falls and initiate urgent cytoreductive therapy.
  *Reference: 6

9.2 Splanchnic Vein Thrombosis

• Treat initially with low‑molecular‑weight heparin, followed by long‑term oral anticoagulation; hydroxyurea may be added to lower platelet count.
  *Reference: 6

9.3 Anticoagulation Adjustment According to Platelet Count

*Reference: 8

10. Diagnostic Pitfalls

• Iron‑deficiency anemia can mask PV by lowering hemoglobin below diagnostic thresholds while maintaining elevated red‑cell mass and low MCV.
  *Reference: 9

• Reactive thrombocytosis (e.g., due to iron deficiency, inflammation, malignancy) must be ruled out, but its presence does not exclude ET if WHO criteria are otherwise met.
  *Reference: 1

• Approximately 10‑15 % of ET cases are triple‑negative (JAK2, CALR, MPL negative) yet still represent a clonal MPN based on marrow histology.
  *Reference: 6

Guidelines for Evaluation and Management of JAK2‑Positive Myeloproliferative Neoplasms

1. Diagnostic Evaluation

• Hemoglobin > 18.5 g/dL in males or > 16.5 g/dL in females, together with a positive JAK2 V617F mutation, fulfills WHO criteria for polycythemia vera (PV). 10
• Sustained platelet count ≥ 450 × 10⁹/L in the setting of JAK2 V617F positivity supports a diagnosis of essential thrombocythemia (ET) or early PV. 10
• Serum erythropoietin level below the normal range is a supportive laboratory feature for PV. 10
• Peripheral‑blood smear showing left‑shifted myeloid cells and morphologic abnormalities aids in distinguishing PV/ET from reactive processes. 10
• Bone‑marrow biopsy with reticulin staining (grade 0‑3) is mandatory before initiating cytoreductive therapy to differentiate PV (panmyelosis, trilineage proliferation), ET (isolated megakaryocytic proliferation), and primary myelofibrosis (PMF) (atypical megakaryocytes with fibrosis). 10, 11

2. Mutation Prevalence

• JAK2 V617F is present in > 95 % of PV cases and in 50‑60 % of ET and PMF cases. 11, 12
• In JAK2‑negative but clinically suspected PV, JAK2 exon 12 mutations account for 2‑4 % of cases.

3. Risk Stratification

3.1 Polycythemia Vera and Essential Thrombocythemia

• High‑risk disease is defined by any of the following: age ≥ 60 years or a prior arterial/venous thrombotic event. 10, 11, 12
• The IPSET‑thrombosis scoring system for ET assigns points as follows: age ≥ 60 years = 1 point; prior thrombosis = 2 points; cardiovascular risk factors = 1 point (smoking, diabetes, hypertension, hypercholesterolemia). A total score of 0‑1 = low risk, 2 = intermediate risk, ≥ 3 = high risk. 12, 13

3.2 Primary Myelofibrosis

• The International Prognostic Scoring System (IPSS) is used at diagnosis, and the Dynamic IPSS (DIPSS) is applied during disease course; both incorporate clinical variables, cytogenetics, and transfusion dependence. 10, 11, 12

4. Treatment Recommendations

4.1 High‑Risk Polycythemia Vera

• Phlebotomy to maintain hematocrit < 45 % (or a lower pregnancy‑specific target). 10, 11, 14
• Low‑dose aspirin 75‑100 mg daily for antiplatelet protection. 10, 11
• Cytoreductive therapy with hydroxyurea or interferon‑α, irrespective of patient age. 10, 11, 12

4.2 High‑Risk Essential Thrombocythemia

• Cytoreductive therapy with hydroxyurea as first‑line, aiming for platelet counts within the normal range. 10, 11
• Low‑dose aspirin 75‑100 mg daily. 10, 11

4.3 Low‑Risk Disease (PV or ET)

• PV: phlebotomy alone to keep hematocrit < 45 % plus low‑dose aspirin. 10, 11
• ET: low‑dose aspirin alone; observation without cytoreduction unless complications arise. 10, 11

4.4 Indications for Cytoreduction in Low‑Risk Patients

• Symptomatic splenomegaly, progressive leukocytosis or thrombocytosis, or intolerance/inadequate response to phlebotomy in PV. 12

4.5 Primary Myelofibrosis

• Anemia management with corticosteroids, androgens, erythropoiesis‑stimulating agents, or immunomodulators. 10, 11
• Splenomegaly: hydroxyurea first‑line; JAK‑inhibitor (ruxolitinib) for symptomatic disease. 10, 11
• Splenectomy for refractory painful splenomegaly, portal hypertension, or transfusion dependence. 10, 11
• Allogeneic stem‑cell transplantation for eligible patients with an expected median survival < 5 years. 10, 11

5. Special Clinical Situations

5.1 Splanchnic Vein Thrombosis

• Initiate low‑molecular‑weight heparin (LMWH) followed by indefinite oral anticoagulation; add hydroxyurea to lower platelet count. 13

5.2 Pregnancy

• Low‑risk pregnancy (no prior thrombosis): phlebotomy to keep hematocrit < 45 %, low‑dose aspirin, and prophylactic‑dose LMWH after delivery for 6 weeks. 14, 12
• High‑risk pregnancy (prior thrombosis or severe complications): therapeutic LMWH throughout gestation; discontinue aspirin if bleeding occurs; consider interferon‑α if platelet count ≥ 1500 × 10⁹/L. 14, 12, 13

6. Monitoring and Follow‑Up

• Perform CBC, physical examination or ultrasound of the spleen, and clinical assessment every 3‑6 months to evaluate treatment response and detect cytopenias or thrombotic/bleeding events. 12
• Apply ELN clinico‑hematologic response criteria for PV and ET to standardize response assessment. 10, 11